Product Name

  • Name

    Dibenz-(b,f)-1,4-oxazephine

  • EINECS
  • CAS No. 257-07-8
  • Article Data26
  • CAS DataBase
  • Density 1.16g/cm3
  • Solubility
  • Melting Point
  • Formula C13H9 N O
  • Boiling Point 329.3°Cat760mmHg
  • Molecular Weight 195.221
  • Flash Point 125°C
  • Transport Information
  • Appearance
  • Safety Poison by intraperitoneal and intravenous routes. Moderately toxic by ingestion and inhalation. Experimental teratogenic and reproductive effects. A human skin and eye irritant. Questionable carcinogen with experimental carcinogenic and tumorigenic data. When heated to decomposition it emits toxic fumes of NOx.
  • Risk Codes
  • Molecular Structure Molecular Structure of 257-07-8 (Dibenz-(b,f)-1,4-oxazephine)
  • Hazard Symbols
  • Synonyms CR; CR(lacrimator); NSC 293779
  • PSA 21.59000
  • LogP 2.97850

Synthetic route

2-Fluorobenzaldehyde
446-52-6

2-Fluorobenzaldehyde

2-amino-phenol
95-55-6

2-amino-phenol

A

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

B

2-(2-fluorophenyl)benzo[d]oxazole
212758-52-6

2-(2-fluorophenyl)benzo[d]oxazole

Conditions
ConditionsYield
With oxygen; 1,3-diethyl-1H-benzo[d]imidazol-3-ium bromide; sodium hydroxide In o-xylene; para-xylene; m-xylene at 120℃; for 10h; Molecular sieve; Green chemistry;A 25%
B 65%
2-Fluorobenzaldehyde
446-52-6

2-Fluorobenzaldehyde

2-amino-phenol
95-55-6

2-amino-phenol

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
With poly(ethylene glycol)-400; potassium carbonate at 100℃; for 8h; Product distribution; Further Variations:; Reagents; Solvents; Temperatures; time;89%
Stage #1: 2-amino-phenol In polyethylene glycol (300) at 50℃; for 0.5h;
Stage #2: 2-Fluorobenzaldehyde In polyethylene glycol (300) at 50℃; for 10h;
Stage #3: With potassium carbonate In polyethylene glycol (300) at 100℃; for 10h;
80%
With potassium carbonate at 100℃; Sealed tube;58%
2-[(2-chlorobenzylidene)amino]phenol
6266-10-0

2-[(2-chlorobenzylidene)amino]phenol

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Stage #1: 2-[(2-chlorobenzylidene)amino]phenol With potassium hydroxide In methanol at 20℃; for 0.583333h;
Stage #2: In dimethyl sulfoxide at 120℃; for 2h; Further stages.;
75%
Stage #1: 2-[(2-chlorobenzylidene)amino]phenol With potassium hydroxide In methanol at 20℃; for 1h;
Stage #2: In dimethyl sulfoxide at 150℃; for 6h;
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
2-chloro-benzaldehyde
89-98-5

2-chloro-benzaldehyde

2-amino-phenol
95-55-6

2-amino-phenol

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
With potassium hydroxide In N,N-dimethyl-formamide at 120℃; for 0.1h; Temperature; Reagent/catalyst; Microwave irradiation;87%
Stage #1: 2-chloro-benzaldehyde; 2-amino-phenol In 5,5-dimethyl-1,3-cyclohexadiene for 2h; Reflux;
Stage #2: In 5,5-dimethyl-1,3-cyclohexadiene at 120℃; for 24h;
Stage #3: With sodium In 5,5-dimethyl-1,3-cyclohexadiene for 6h; Reflux;
75%
phenylacetylene
536-74-3

phenylacetylene

2-amino-phenol
95-55-6

2-amino-phenol

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
With tetrabutylammonium acetate; palladium diacetate; 1,2-diamino-benzene In N,N-dimethyl-formamide at 120℃; Microwave irradiation;82%
N-(2-phenoxyphenyl)formamide
2770-12-9

N-(2-phenoxyphenyl)formamide

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
With polyphosphiric acid; trichlorophosphate at 120 - 130℃; for 2h; Cyclization;75%
2-formamido-4'-tert-butyldiphenyl ester

2-formamido-4'-tert-butyldiphenyl ester

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
With polyphosphiric acid; trichlorophosphate at 120 - 130℃; for 2h; Cyclization;56%
benzaldehyde
100-52-7

benzaldehyde

2-amino-phenol
95-55-6

2-amino-phenol

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
With potassium carbonate at 100℃; for 5h;68%
2-amino-phenol
95-55-6

2-amino-phenol

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
2-formamido-4'-tert-butyldiphenyl ester

2-formamido-4'-tert-butyldiphenyl ester

A

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

B

2-tert-butyl-dibenzo[b,f][1,4]oxazepine

2-tert-butyl-dibenzo[b,f][1,4]oxazepine

Conditions
ConditionsYield
With polyphosphiric acid; trichlorophosphate at 120 - 130℃; for 2h; Cyclization;A 23%
B 31%
2-Fluorobenzaldehyde
446-52-6

2-Fluorobenzaldehyde

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
Multi-step reaction with 3 steps
1: potassium tert-butylate / N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
Multi-step reaction with 3 steps
1: sodium hydrogencarbonate / N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
2-(2-nitrophenoxy)benzaldehyde
66961-19-1

2-(2-nitrophenoxy)benzaldehyde

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
With iron In methanol; water for 6h; Reflux;
2-phenoxybenzamide
72084-13-0

2-phenoxybenzamide

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
With PPA at 120 - 130℃; Cyclization;
C13H9FNO(1-)*K(1+)

C13H9FNO(1-)*K(1+)

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 140℃; Microwave irradiation;
C13H9FNO(1-)*Na(1+)

C13H9FNO(1-)*Na(1+)

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 140℃; Microwave irradiation;
C13H10FNO

C13H10FNO

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 140℃; Microwave irradiation;
C13H10ClNO

C13H10ClNO

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 140℃; Microwave irradiation;
C13H10BrNO

C13H10BrNO

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 140℃; Microwave irradiation;
C13H10INO

C13H10INO

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 140℃; Microwave irradiation;
2-chloro-benzaldehyde
89-98-5

2-chloro-benzaldehyde

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
ortho-bromobenzaldehyde
6630-33-7

ortho-bromobenzaldehyde

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
2-iodobenzaldehyde
26260-02-6

2-iodobenzaldehyde

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
3: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
C13H9FNO(1-)*K(1+)

C13H9FNO(1-)*K(1+)

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
C13H9FNO(1-)*Na(1+)

C13H9FNO(1-)*Na(1+)

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
GRI 378898
2805-76-7

GRI 378898

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
2-Hydroxy-N-<2-brom-benzyliden>-anilin
36456-43-6

2-Hydroxy-N-<2-brom-benzyliden>-anilin

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
C13H10INO
218280-60-5

C13H10INO

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
2: N,N-dimethyl-formamide / 140 °C / Microwave irradiation
View Scheme
S-phenyl 2-diazoethanethiolate
72228-26-3

S-phenyl 2-diazoethanethiolate

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

(+/-)-trans-2-phenylthioazeto[1,2-d]dibenzo[b,f]oxazepin-1-one

(+/-)-trans-2-phenylthioazeto[1,2-d]dibenzo[b,f]oxazepin-1-one

Conditions
ConditionsYield
In toluene at 80℃; for 1.5h; Staudinger reaction;99%
In benzene at 80℃; for 1h;99%
indole
120-72-9

indole

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

2-(2-(di(1H-indol-3-yl)methyl)phenoxy)aniline

2-(2-(di(1H-indol-3-yl)methyl)phenoxy)aniline

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 3h; Catalytic behavior; Solvent; Friedel-Crafts Alkylation;99%
5-benzyloxy-1H-indole
1215-59-4

5-benzyloxy-1H-indole

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

2-(2-(bis(5-(benzyloxy)-1H-indol-3-yl)methyl)phenoxy)aniline

2-(2-(bis(5-(benzyloxy)-1H-indol-3-yl)methyl)phenoxy)aniline

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 3h; Friedel-Crafts Alkylation;99%
7-methyl-1H-indole
933-67-5

7-methyl-1H-indole

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

2-(2-(bis(7-methyl-1H-indol-3-yl)methyl)phenoxy)aniline

2-(2-(bis(7-methyl-1H-indol-3-yl)methyl)phenoxy)aniline

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 3h; Friedel-Crafts Alkylation;99%
dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

10H-dibenzo[b,f][1,4]oxazepin-11-one
3158-85-8

10H-dibenzo[b,f][1,4]oxazepin-11-one

Conditions
ConditionsYield
With dipotassium peroxodisulfate In ethanol; N,N-dimethyl-formamide at 50℃; for 1h; Time; Reagent/catalyst;98%
5-methoxylindole
1006-94-6

5-methoxylindole

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

2-(2-(bis(5-methoxy-1H-indol-3-yl)methyl)phenoxy)aniline

2-(2-(bis(5-methoxy-1H-indol-3-yl)methyl)phenoxy)aniline

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 1.5h; Friedel-Crafts Alkylation;98%
1,5,7-trimethyl-3-diazooxindole

1,5,7-trimethyl-3-diazooxindole

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

spiro[5,7-dimethyloxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

spiro[5,7-dimethyloxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

Conditions
ConditionsYield
With toluene-4-sulfonic acid In tetrahydrofuran at 15 - 20℃; for 24h; diastereoselective reaction;93%
3-diazo-1-methyl-1,3-dihydro-indol-2-one
3265-14-3

3-diazo-1-methyl-1,3-dihydro-indol-2-one

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

spiro[1-methyloxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

spiro[1-methyloxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

Conditions
ConditionsYield
With toluene-4-sulfonic acid In tetrahydrofuran at 15 - 20℃; for 24h; diastereoselective reaction;93%
3-diazo-1-methyl-1,3-dihydro-indol-2-one
3265-14-3

3-diazo-1-methyl-1,3-dihydro-indol-2-one

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

C35H25N3O3

C35H25N3O3

Conditions
ConditionsYield
With p-toluenesulfonic acid monohydrate In tetrahydrofuran at 20℃; for 24h; Reagent/catalyst; diastereoselective reaction;93%
C10H9N3O
1416060-68-8

C10H9N3O

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

C36H27N3O3

C36H27N3O3

Conditions
ConditionsYield
In tetrahydrofuran at 20℃; for 24h; diastereoselective reaction;93%
trimethylsilyl cyanide
7677-24-9

trimethylsilyl cyanide

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

(R)-10,11-dihydrodibenzo[b,f][1,4]oxazepine-11-carbonitrile

(R)-10,11-dihydrodibenzo[b,f][1,4]oxazepine-11-carbonitrile

Conditions
ConditionsYield
With 1-[3,5-bis(trifluoromethyl)phenyl]-3-{(S)[(2S,4S,5R)-5-ethyl-1-aza-bicyclo[2.2.2]oct-2-yl]-(6-methoxy-4-quinolinyl)methyl}thiourea; 2,2,2-trifluoroethanol In 1,2-dichloro-ethane at 4℃; for 30h; Catalytic behavior; Reagent/catalyst; Solvent; Temperature; enantioselective reaction;93%
1-ethenylcyclohexene
931-49-7

1-ethenylcyclohexene

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

(R)-11-(cyclohexenylethynyl)-10,11-dihydrodibenzo[b,f][1,4]oxazepine

(R)-11-(cyclohexenylethynyl)-10,11-dihydrodibenzo[b,f][1,4]oxazepine

Conditions
ConditionsYield
With (S)-CPA; silver(I) acetate In 1,4-dioxane at 15℃; for 72h; enantioselective reaction;92%
butanone
78-93-3

butanone

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

(R)-1-(10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)butan-2-one

(R)-1-(10,11-dihydrodibenzo[b,f][1,4]oxazepin-11-yl)butan-2-one

Conditions
ConditionsYield
With L-proline In N,N-dimethyl-formamide at 20℃; Molecular sieve; enantioselective reaction;92%
dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

1-benzyl-3-diazo-1,3-dihydro-2H-indol-2-one
461677-71-4

1-benzyl-3-diazo-1,3-dihydro-2H-indol-2-one

spiro[1-benzyloxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

spiro[1-benzyloxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

Conditions
ConditionsYield
With toluene-4-sulfonic acid In tetrahydrofuran at 15 - 20℃; for 24h; diastereoselective reaction;92%
dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

1-benzoyl-3- diazoindolin-2-one
20352-79-8

1-benzoyl-3- diazoindolin-2-one

spiro[1-benzoyloxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

spiro[1-benzoyloxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

Conditions
ConditionsYield
With toluene-4-sulfonic acid In tetrahydrofuran at 15 - 20℃; for 24h; diastereoselective reaction;92%
dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

1-benzyl-3-diazo-1,3-dihydro-2H-indol-2-one
461677-71-4

1-benzyl-3-diazo-1,3-dihydro-2H-indol-2-one

C41H29N3O3

C41H29N3O3

Conditions
ConditionsYield
With p-toluenesulfonic acid monohydrate In diethyl ether at 20℃; for 24h; Reagent/catalyst; Solvent; diastereoselective reaction;92%
dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

1-benzoyl-3- diazoindolin-2-one
20352-79-8

1-benzoyl-3- diazoindolin-2-one

C41H27N3O4

C41H27N3O4

Conditions
ConditionsYield
In para-xylene at 20℃; for 24h; diastereoselective reaction;92%
5-methoxylindole
1006-94-6

5-methoxylindole

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

11-(5-methoxy-1H-indol-3-yl)-10,11-dihydrodibenzo[b,f][1,4]oxazepine

11-(5-methoxy-1H-indol-3-yl)-10,11-dihydrodibenzo[b,f][1,4]oxazepine

Conditions
ConditionsYield
With trifluoroacetic acid In tetrahydrofuran at 20℃; for 0.5h; Friedel-Crafts Alkylation;91%
1-methylindole
603-76-9

1-methylindole

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

11-(1-methyl-1H-indol-3-yl)-10,11-dihydrodibenzo[b,f][1,4]oxazepine

11-(1-methyl-1H-indol-3-yl)-10,11-dihydrodibenzo[b,f][1,4]oxazepine

Conditions
ConditionsYield
With trifluoroacetic acid In tetrahydrofuran at 20℃; for 1.5h; Friedel-Crafts Alkylation;91%
3-diazo-indolin-2-one
3265-29-0

3-diazo-indolin-2-one

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

spiro[oxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

spiro[oxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

Conditions
ConditionsYield
With toluene-4-sulfonic acid In tetrahydrofuran at 15 - 20℃; for 24h; Solvent; Temperature; Reagent/catalyst; diastereoselective reaction;91%
tert-butyl 3-diazo-2-oxoindoline-1-carboxylate
1419184-25-0

tert-butyl 3-diazo-2-oxoindoline-1-carboxylate

dibenz[b,f][1,4]oxazepine
257-07-8

dibenz[b,f][1,4]oxazepine

spiro[tert-butyl-1-carboxylateoxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

spiro[tert-butyl-1-carboxylateoxindole-imidazo-bis(tetrahydro-dibenzo[1,4]oxazepine)]

Conditions
ConditionsYield
With toluene-4-sulfonic acid In tetrahydrofuran at 15 - 20℃; for 24h; diastereoselective reaction;91%

DIBENZ(b,f)(1,4)OXAZEPINE Chemical Properties

Product Name: Dibenz(b,f)(1,4)oxazepine (CAS NO.257-07-8)


Molecular Formula: C13H9NO
Molecular Weight: 195.21666g/mol
Mol File: 257-07-8.mol
Boiling point: 329.3 °C at 760 mmHg
Flash Point: 125 °C
Density: 1.16 g/cm3
Surface Tension: 43.7 dyne/cm
Enthalpy of Vaporization: 54.91 kJ/mol
Vapour Pressure: 0.000342 mmHg at 25°C
XLogP3-AA: 2.6
H-Bond Donor: 0
H-Bond Acceptor: 2

DIBENZ(b,f)(1,4)OXAZEPINE Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
guinea pig LCLo inhalation 1500mg/m3/2H (1500mg/m3)   Toxicology. Vol. 8, Pg. 347, 1977.
guinea pig LD50 intraperitoneal 463mg/kg (463mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: ATAXIA

SKIN AND APPENDAGES (SKIN): HAIR: OTHER
Toxicology. Vol. 8, Pg. 347, 1977.
guinea pig LD50 oral 629mg/kg (629mg/kg) BEHAVIORAL: GENERAL ANESTHETIC

BEHAVIORAL: ATAXIA

BEHAVIORAL: COMA
Toxicology. Vol. 8, Pg. 347, 1977.
hamster LCLo inhalation 1850mg/m3/3H (1850mg/m3)   Toxicology. Vol. 8, Pg. 347, 1977.
mouse LCLo inhalation 1500mg/m3/2H (1500mg/m3)   Toxicology. Vol. 8, Pg. 347, 1977.
mouse LD50 intraperitoneal 242mg/kg (242mg/kg)   Interagency Collaborative Group on Environmental Carcinogenesis, National Cancer Institute, Memorandum, June 17, 1974Vol. 17JUN1974,
mouse LD50 intravenous 37200ug/kg (37.2mg/kg)   Interagency Collaborative Group on Environmental Carcinogenesis, National Cancer Institute, Memorandum, June 17, 1974Vol. 17JUN1974,
mouse LD50 oral 770mg/kg (770mg/kg)   Interagency Collaborative Group on Environmental Carcinogenesis, National Cancer Institute, Memorandum, June 17, 1974Vol. 17JUN1974,
rabbit LCLo inhalation 1500mg/m3/2H (1500mg/m3)   Toxicology. Vol. 8, Pg. 347, 1977.
rabbit LD50 intravenous 26mg/kg (26mg/kg)   Interagency Collaborative Group on Environmental Carcinogenesis, National Cancer Institute, Memorandum, June 17, 1974Vol. 17JUN1974,
rabbit LD50 oral 1760mg/kg (1760mg/kg) BEHAVIORAL: GENERAL ANESTHETIC

BEHAVIORAL: COMA

BEHAVIORAL: ATAXIA
Toxicology. Vol. 8, Pg. 347, 1977.
rabbit LD50 skin > 400mg/kg (400mg/kg)   Toxicology. Vol. 8, Pg. 347, 1977.
rat LD50 intraperitoneal 164mg/kg (164mg/kg)   Interagency Collaborative Group on Environmental Carcinogenesis, National Cancer Institute, Memorandum, June 17, 1974Vol. 17JUN1974,
rat LD50 intravenous 26mg/kg (26mg/kg)   Interagency Collaborative Group on Environmental Carcinogenesis, National Cancer Institute, Memorandum, June 17, 1974Vol. 17JUN1974,
rat LD50 oral 563mg/kg (563mg/kg)   Interagency Collaborative Group on Environmental Carcinogenesis, National Cancer Institute, Memorandum, June 17, 1974Vol. 17JUN1974,

DIBENZ(b,f)(1,4)OXAZEPINE Consensus Reports

Reported in EPA TSCA Inventory.

DIBENZ(b,f)(1,4)OXAZEPINE Safety Profile

Poison by intraperitoneal and intravenous routes. Moderately toxic by ingestion and inhalation. Experimental teratogenic and reproductive effects. A human skin and eye irritant. Questionable carcinogen with experimental carcinogenic and tumorigenic data. When heated to decomposition it emits toxic fumes of NOx.

DIBENZ(b,f)(1,4)OXAZEPINE Specification

 Dibenz(b,f)(1,4)oxazepine ,its CAS NO. is 257-07-8,the synonyms is Dibenz(b,f)(1,4)oxazepine ; Dibenzo(b,f)-1,4oxazepine ; Dibenz-1,4-oxazepine ; Ea-3547 .

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View